nilotinib ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1932 641571-10-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nilotinib hydrochloride hydrate
  • nilotinib
  • tasigna
  • nilotinib hydrochloride monohydrate
Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.
  • Molecular weight: 529.53
  • Formula: C28H22F3N7O
  • CLOGP: 5.69
  • LIPINSKI: 2
  • HAC: 8
  • HDO: 2
  • TPSA: 97.62
  • ALOGS: -5.42
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.58 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 29, 2007 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytogenetic analysis abnormal 617.53 16.17 124 21631 796 63466471
Peripheral arterial occlusive disease 355.71 16.17 107 21648 4094 63463173
Electrocardiogram QT prolonged 346.19 16.17 229 21526 59301 63407966
Blast crisis in myelogenous leukaemia 245.46 16.17 53 21702 504 63466763
Drug resistance 218.00 16.17 121 21634 22812 63444455
Second primary malignancy 217.20 16.17 87 21668 7866 63459401
Chronic myeloid leukaemia transformation 212.37 16.17 37 21718 91 63467176
Lipase increased 189.12 16.17 84 21671 9816 63457451
Philadelphia chromosome positive 180.98 16.17 39 21716 367 63466900
Pleural effusion 167.17 16.17 182 21573 93028 63374239
Rash 138.89 16.17 464 21291 560407 62906860
Bone pain 127.51 16.17 123 21632 54518 63412749
Blood bilirubin increased 127.39 16.17 104 21651 37036 63430231
Myocardial infarction 122.88 16.17 161 21594 99732 63367535
Intermittent claudication 118.44 16.17 38 21717 1801 63465466
Malignant neoplasm progression 116.29 16.17 142 21613 81979 63385288
Peripheral artery stenosis 114.37 16.17 29 21726 579 63466688
Off label use 106.88 16.17 49 21706 674413 62792854
Chronic myeloid leukaemia recurrent 95.58 16.17 21 21734 218 63467049
Death 95.26 16.17 313 21442 374068 63093199
Thrombocytopenia 95.15 16.17 179 21576 150978 63316289
Acute myocardial infarction 91.79 16.17 81 21674 32043 63435224
Arteriosclerosis 89.88 16.17 51 21704 10015 63457252
Platelet count decreased 85.16 16.17 147 21608 115975 63351292
Pancreatitis 84.76 16.17 94 21661 48961 63418306
Myalgia 81.82 16.17 165 21590 146364 63320903
White blood cell count increased 77.00 16.17 89 21666 48472 63418795
Acute lymphocytic leukaemia recurrent 69.58 16.17 27 21728 2242 63465025
Angina pectoris 68.80 16.17 67 21688 30011 63437256
Peripheral vascular disorder 66.10 16.17 35 21720 6000 63461267
Platelet count increased 65.82 16.17 52 21703 17659 63449608
Condition aggravated 63.90 16.17 29 21726 402188 63065079
Pancytopenia 63.70 16.17 117 21638 96816 63370451
Joint swelling 63.40 16.17 17 21738 327649 63139618
Haematotoxicity 61.60 16.17 39 21716 9337 63457930
Pruritus 60.12 16.17 264 21491 361189 63106078
Blast cell crisis 59.73 16.17 12 21743 77 63467190
Cerebrovascular accident 57.14 16.17 119 21636 107905 63359362
Arthropathy 56.49 16.17 7 21748 234785 63232482
Systemic lupus erythematosus 56.15 16.17 4 21751 208914 63258353
Normal newborn 55.56 16.17 35 21720 8306 63458961
Gene mutation identification test positive 54.15 16.17 12 21743 130 63467137
Carotid artery stenosis 53.86 16.17 29 21726 5141 63462126
Myocardial ischaemia 52.67 16.17 40 21715 12819 63454448
Hyperbilirubinaemia 52.64 16.17 38 21717 11276 63455991
Pericardial effusion 52.60 16.17 58 21697 30000 63437267
Rheumatoid arthritis 51.33 16.17 12 21743 253807 63213460
Splenomegaly 50.83 16.17 37 21718 11120 63456147
Therapeutic response delayed 48.06 16.17 15 21740 649 63466618
Glossodynia 46.45 16.17 4 21751 178872 63288395
Exposure via father 46.39 16.17 12 21743 260 63467007
Labelled drug-food interaction medication error 45.85 16.17 11 21744 173 63467094
Blood glucose increased 45.14 16.17 93 21662 83663 63383604
Exposure via partner 44.34 16.17 10 21745 118 63467149
Coronary artery disease 44.19 16.17 55 21700 32322 63434945
Anaemia 44.01 16.17 208 21547 293222 63174045
Thrombocytosis 42.78 16.17 26 21729 5792 63461475
Polymerase chain reaction positive 42.56 16.17 10 21745 143 63467124
Diabetes mellitus 41.32 16.17 71 21684 55739 63411528
Drug hypersensitivity 41.21 16.17 28 21727 310659 63156608
Bone marrow failure 40.36 16.17 50 21705 29240 63438027
Dry skin 40.33 16.17 71 21684 56816 63410451
Drug ineffective 39.25 16.17 205 21550 1044560 62422707
Chronic myeloid leukaemia 38.97 16.17 18 21737 2300 63464967
Arterial disorder 38.64 16.17 15 21740 1246 63466021
Xanthelasma 38.28 16.17 8 21747 64 63467203
Amylase increased 38.24 16.17 25 21730 6320 63460947
Palpitations 37.71 16.17 104 21651 112666 63354601
Cytopenia 36.66 16.17 31 21724 11570 63455697
Arterial occlusive disease 34.75 16.17 23 21732 5935 63461332
Leukaemia recurrent 34.33 16.17 14 21741 1324 63465943
Product use issue 33.28 16.17 17 21738 220503 63246764
Musculoskeletal stiffness 33.08 16.17 11 21744 184607 63282660
Skin disorder 32.33 16.17 45 21710 29462 63437805
Concomitant disease aggravated 32.24 16.17 26 21729 9086 63458181
Acute coronary syndrome 31.88 16.17 27 21728 10099 63457168
Basophil count increased 31.53 16.17 12 21743 945 63466322
Peripheral artery occlusion 31.33 16.17 13 21742 1285 63465982
Concomitant disease progression 31.05 16.17 15 21740 2119 63465148
Intentional product use issue 30.28 16.17 4 21751 127888 63339379
Food interaction 29.39 16.17 11 21744 827 63466440
Sinusitis 29.27 16.17 21 21734 226632 63240635
Peripheral ischaemia 28.86 16.17 19 21736 4859 63462408
Wound 28.77 16.17 10 21745 163253 63304014
Discomfort 28.24 16.17 11 21744 167363 63299904
Gamma-glutamyltransferase increased 27.46 16.17 45 21710 33986 63433281
Lower respiratory tract infection 27.24 16.17 6 21749 132301 63334966
Abdominal pain upper 27.11 16.17 141 21614 206303 63260964
Hypersensitivity 26.49 16.17 37 21718 292648 63174619
Abdominal pain 26.10 16.17 181 21574 293275 63173992
Pain in extremity 25.22 16.17 197 21558 331289 63135978
Hypotension 25.13 16.17 34 21721 272570 63194697
Muscle spasms 25.07 16.17 113 21642 156037 63311230
Cardiac failure 24.79 16.17 77 21678 89065 63378202
Impaired healing 24.78 16.17 3 21752 102539 63364728
Pregnancy of partner 24.77 16.17 5 21750 33 63467234
Blast cell count increased 23.82 16.17 8 21747 438 63466829
Swelling 23.75 16.17 36 21719 275342 63191925
Transaminases increased 23.33 16.17 40 21715 31327 63435940
Acute kidney injury 23.14 16.17 34 21721 263381 63203886
Alanine aminotransferase increased 22.97 16.17 83 21672 103687 63363580
Fluid retention 22.94 16.17 58 21697 59628 63407639
Haemolytic transfusion reaction 22.91 16.17 4 21751 10 63467257
Gangrene 22.79 16.17 18 21737 6105 63461162
Chest pain 22.72 16.17 139 21616 215820 63251447
Keratosis pilaris 22.66 16.17 5 21750 53 63467214
Atrial fibrillation 22.28 16.17 89 21666 116547 63350720
Mobility decreased 22.08 16.17 7 21748 121152 63346115
Stomatitis 21.98 16.17 10 21745 138715 63328552
Hyperglycaemia 21.97 16.17 46 21709 41821 63425446
Leukocytosis 21.88 16.17 35 21720 25900 63441367
Therapeutic response decreased 21.81 16.17 58 21697 61467 63405800
Collateral circulation 21.49 16.17 4 21751 16 63467251
Confusional state 21.26 16.17 30 21725 236350 63230917
Hepatic function abnormal 20.89 16.17 42 21713 37100 63430167
Neoplasm malignant 20.81 16.17 37 21718 29824 63437443
Exposure during pregnancy 20.62 16.17 14 21741 155533 63311734
Blood lactate dehydrogenase increased 20.61 16.17 32 21723 23084 63444183
Coronary artery insufficiency 20.31 16.17 5 21750 88 63467179
Haemoglobin decreased 20.23 16.17 101 21654 145384 63321883
Pericarditis 20.06 16.17 10 21745 131569 63335698
Dyslipidaemia 19.83 16.17 18 21737 7375 63459892
Toxicity to various agents 19.74 16.17 34 21721 247216 63220051
Hypercholesterolaemia 19.68 16.17 30 21725 21304 63445963
Pancreatic enzymes increased 19.64 16.17 8 21747 754 63466513
Jaundice 18.80 16.17 35 21720 29216 63438051
Cerebrovascular stenosis 18.72 16.17 4 21751 36 63467231
Overdose 18.69 16.17 8 21747 115070 63352197
Skin sensitisation 18.45 16.17 8 21747 881 63466386
Hepatic infection 18.38 16.17 7 21748 552 63466715
Ill-defined disorder 18.33 16.17 3 21752 81752 63385515
Oxygen saturation decreased 18.26 16.17 4 21751 88581 63378686
Angiopathy 18.12 16.17 14 21741 4599 63462668
Fibromyalgia 17.92 16.17 3 21752 80417 63386850
Coronary artery stenosis 17.77 16.17 14 21741 4730 63462537
Calculus bladder 17.60 16.17 7 21748 620 63466647
Cerebral infarction 17.16 16.17 30 21725 23863 63443404
Therapeutic product effect incomplete 16.92 16.17 11 21744 125045 63342222
Extremity necrosis 16.67 16.17 9 21746 1604 63465663
Vertebral artery stenosis 16.61 16.17 4 21751 64 63467203
Gene mutation 16.40 16.17 9 21746 1656 63465611
Oncologic complication 16.40 16.17 5 21750 200 63467067

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytogenetic analysis abnormal 452.94 14.99 104 23296 635 34932896
Blast crisis in myelogenous leukaemia 397.06 14.99 90 23310 514 34933017
Second primary malignancy 384.80 14.99 158 23242 7728 34925803
Electrocardiogram QT prolonged 380.88 14.99 272 23128 40680 34892851
Peripheral arterial occlusive disease 375.24 14.99 143 23257 5731 34927800
Drug resistance 228.94 14.99 167 23233 25760 34907771
Angina pectoris 224.00 14.99 178 23222 31185 34902346
Pleural effusion 222.06 14.99 273 23127 81273 34852258
Intermittent claudication 218.29 14.99 75 23325 2219 34931312
Myocardial infarction 176.01 14.99 301 23099 120784 34812747
Rash 163.55 14.99 418 22982 222334 34711197
Lipase increased 158.41 14.99 91 23309 9325 34924206
Death 158.40 14.99 603 22797 397446 34536085
Off label use 156.48 14.99 44 23356 419480 34514051
Drug intolerance 153.31 14.99 194 23206 59376 34874155
Chronic myeloid leukaemia transformation 138.81 14.99 30 23370 132 34933399
Coronary artery stenosis 128.15 14.99 80 23320 9536 34923995
Chronic myeloid leukaemia recurrent 121.20 14.99 28 23372 176 34933355
Philadelphia chromosome positive 118.49 14.99 31 23369 345 34933186
Pancreatitis 103.72 14.99 129 23271 38762 34894769
Blood bilirubin increased 100.48 14.99 126 23274 38170 34895361
Peripheral artery stenosis 96.74 14.99 32 23368 840 34932691
Malignant neoplasm progression 92.89 14.99 191 23209 87855 34845676
Acute myocardial infarction 92.00 14.99 144 23256 53575 34879956
White blood cell count increased 88.79 14.99 123 23277 41028 34892503
Myocardial ischaemia 85.87 14.99 80 23320 17328 34916203
Peripheral vascular disorder 85.57 14.99 49 23351 4987 34928544
Coronary artery disease 84.82 14.99 131 23269 48174 34885357
Acute kidney injury 84.33 14.99 50 23350 304938 34628593
Arterial disorder 81.62 14.99 31 23369 1228 34932303
Platelet count decreased 79.70 14.99 217 23183 119500 34814031
Hypotension 66.05 14.99 33 23367 221616 34711915
Carotid artery stenosis 64.96 14.99 41 23359 4978 34928553
Abdominal pain upper 62.69 14.99 144 23256 71346 34862185
Toxicity to various agents 60.95 14.99 29 23371 200333 34733198
Concomitant disease aggravated 60.19 14.99 41 23359 5660 34927871
Acute coronary syndrome 58.76 14.99 58 23342 13487 34920044
Chest pain 57.48 14.99 201 23199 126561 34806970
Peripheral artery occlusion 56.33 14.99 26 23374 1686 34931845
Thrombocytopenia 56.17 14.99 230 23170 156017 34777514
Polymerase chain reaction positive 56.09 14.99 14 23386 127 34933404
Concomitant disease progression 55.21 14.99 29 23371 2489 34931042
Blast cell crisis 55.18 14.99 13 23387 90 34933441
Gene mutation identification test positive 54.51 14.99 14 23386 144 34933387
Splenomegaly 53.44 14.99 58 23342 15059 34918472
Arterial stenosis 52.25 14.99 22 23378 1144 34932387
Arteriosclerosis 51.45 14.99 51 23349 11917 34921614
Bone pain 49.41 14.99 65 23335 20621 34912910
Loss of therapeutic response 46.70 14.99 17 23383 597 34932934
Exposure via father 46.67 14.99 12 23388 124 34933407
Labelled drug-food interaction medication error 42.13 14.99 9 23391 37 34933494
Pruritus 40.40 14.99 195 23205 141786 34791745
Peripheral ischaemia 39.95 14.99 32 23368 5655 34927876
Gene mutation 39.02 14.99 19 23381 1389 34932142
Angina unstable 38.23 14.99 43 23357 11610 34921921
Cerebral infarction 38.10 14.99 67 23333 27388 34906143
Overdose 36.77 14.99 8 23392 91051 34842480
Confusional state 36.51 14.99 26 23374 144134 34789397
Therapeutic response decreased 36.19 14.99 68 23332 29245 34904286
Cerebral artery stenosis 35.34 14.99 12 23388 342 34933189
Acoustic neuroma 34.99 14.99 10 23390 158 34933373
Amylase increased 34.49 14.99 30 23370 5938 34927593
Condition aggravated 34.47 14.99 47 23353 192149 34741382
Infarction 34.41 14.99 22 23378 2731 34930800
Chronic myeloid leukaemia 33.45 14.99 20 23380 2204 34931327
Fall 33.09 14.99 53 23347 202832 34730699
Cerebrovascular accident 32.94 14.99 128 23272 84683 34848848
Myalgia 32.72 14.99 127 23273 83983 34849548
Hyperglycaemia 31.83 14.99 77 23323 39403 34894128
Paternal exposure during pregnancy 30.87 14.99 7 23393 40 34933491
Blood glucose increased 30.36 14.99 106 23294 66612 34866919
Pericardial effusion 30.18 14.99 57 23343 24605 34908926
Leukocytosis 29.92 14.99 56 23344 24009 34909522
Hypercholesterolaemia 29.89 14.99 33 23367 8729 34924802
Arterial thrombosis 29.16 14.99 16 23384 1499 34932032
Drug interaction 29.04 14.99 68 23332 225878 34707653
Coronary artery occlusion 28.61 14.99 36 23364 10926 34922605
Oedematous pancreatitis 27.82 14.99 11 23389 486 34933045
Cardiovascular disorder 27.81 14.99 34 23366 10022 34923509
Drug hypersensitivity 27.10 14.99 10 23390 80519 34853012
Tremor 26.57 14.99 11 23389 82576 34850955
Myopathy toxic 26.07 14.99 11 23389 575 34932956
Karyotype analysis abnormal 24.71 14.99 6 23394 48 34933483
Diabetes mellitus 24.45 14.99 78 23322 46795 34886736
Ischaemia 24.43 14.99 22 23378 4558 34928973
Gangrene 24.41 14.99 22 23378 4564 34928967
Hallucination 24.17 14.99 3 23397 51495 34882036
Dehydration 24.08 14.99 31 23369 129938 34803593
Fatigue 23.91 14.99 364 23036 370289 34563242
Clonal evolution 23.70 14.99 7 23393 125 34933406
Hyponatraemia 23.56 14.99 13 23387 82678 34850853
Pain in extremity 23.49 14.99 155 23245 126358 34807173
Muscle spasms 22.74 14.99 105 23295 74896 34858635
Gamma-glutamyltransferase increased 22.48 14.99 56 23344 29175 34904356
Central nervous system leukaemia 22.05 14.99 8 23392 278 34933253
Agitation 21.30 14.99 6 23394 57393 34876138
Blast cells present 20.91 14.99 9 23391 494 34933037
Chloroma 20.52 14.99 9 23391 517 34933014
Product blister packaging issue 20.32 14.99 6 23394 107 34933424
Necrosis 20.29 14.99 22 23378 5701 34927830
Arteritis 19.99 14.99 8 23392 365 34933166
Basophil count increased 19.98 14.99 9 23391 551 34932980
Atrial fibrillation 19.79 14.99 145 23255 122248 34811283
Myeloproliferative neoplasm 19.71 14.99 9 23391 569 34932962
Intentional overdose 19.42 14.99 3 23397 43671 34889860
Febrile neutropenia 19.36 14.99 39 23361 136810 34796721
Gelatinous transformation of the bone marrow 19.23 14.99 4 23396 14 34933517
Hepatic infection 18.81 14.99 9 23391 633 34932898
Abdominal pain 18.56 14.99 179 23221 163439 34770092
Chest discomfort 18.54 14.99 79 23321 54451 34879080
Intentional product misuse 18.42 14.99 4 23396 45607 34887924
Bone marrow failure 18.39 14.99 52 23348 29201 34904330
Haemoglobin decreased 18.35 14.99 141 23259 120631 34812900
Headache 18.30 14.99 210 23190 200425 34733106
Acne 18.00 14.99 29 23371 11037 34922494
Leukaemia recurrent 17.97 14.99 12 23388 1603 34931928
Arterial occlusive disease 17.76 14.99 18 23382 4316 34929215
Intentional product use issue 17.63 14.99 9 23391 59807 34873724
Cytopenia 17.58 14.99 31 23369 12692 34920839
Rectosigmoid cancer 17.54 14.99 6 23394 175 34933356
Delirium 17.48 14.99 4 23396 43987 34889544
Acquired gene mutation 17.36 14.99 11 23389 1344 34932187
Vascular stenosis 17.19 14.99 6 23394 186 34933345
Oncologic complication 17.07 14.99 7 23393 340 34933191
Pulmonary hypertension 17.06 14.99 41 23359 20883 34912648
B-cell small lymphocytic lymphoma 16.75 14.99 6 23394 201 34933330
Angiopathy 16.50 14.99 17 23383 4156 34929375
Rheumatoid arthritis 16.18 14.99 3 23397 38235 34895296
Oxygen saturation decreased 16.00 14.99 8 23392 53810 34879721
Pancreatic toxicity 15.50 14.99 4 23396 42 34933489
Somnolence 15.43 14.99 32 23368 111084 34822447
Metabolic acidosis 15.42 14.99 5 23395 43675 34889856
Gait apraxia 15.32 14.99 3 23397 7 34933524
Neoplasm malignant 15.16 14.99 38 23362 19867 34913664
Pulmonary embolism 15.02 14.99 23 23377 89723 34843808

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytogenetic analysis abnormal 827.14 14.81 168 30122 1022 79713076
Peripheral arterial occlusive disease 456.97 14.81 156 30134 8102 79705996
Electrocardiogram QT prolonged 450.30 14.81 329 29961 90057 79624041
Blast crisis in myelogenous leukaemia 431.66 14.81 93 30197 780 79713318
Second primary malignancy 424.16 14.81 171 30119 14179 79699919
Drug resistance 349.44 14.81 211 30079 42002 79672096
Pleural effusion 323.87 14.81 334 29956 144928 79569170
Chronic myeloid leukaemia transformation 267.15 14.81 51 30239 212 79713886
Lipase increased 255.87 14.81 125 30165 16341 79697757
Philadelphia chromosome positive 223.40 14.81 52 30238 638 79713460
Myocardial infarction 203.29 14.81 297 29993 183832 79530266
Rash 200.05 14.81 575 29715 577783 79136315
Angina pectoris 197.62 14.81 161 30129 51571 79662527
Intermittent claudication 197.58 14.81 67 30223 3404 79710694
Blood bilirubin increased 184.16 14.81 172 30118 66060 79648038
Death 176.59 14.81 543 29747 565971 79148127
Platelet count decreased 175.57 14.81 286 30004 194378 79519720
Off label use 154.91 14.81 76 30214 907139 78806959
Acute myocardial infarction 139.67 14.81 159 30131 76877 79637221
Malignant neoplasm progression 139.43 14.81 212 30078 135778 79578320
Peripheral artery stenosis 135.97 14.81 40 30250 1271 79712827
Chronic myeloid leukaemia recurrent 125.78 14.81 28 30262 277 79713821
White blood cell count increased 118.60 14.81 144 30146 74489 79639609
Pancreatitis 111.72 14.81 134 30156 68441 79645657
Bone pain 104.33 14.81 117 30173 55625 79658473
Myocardial ischaemia 100.74 14.81 81 30209 25438 79688660
Thrombocytopenia 100.37 14.81 273 30017 264986 79449112
Gene mutation identification test positive 96.96 14.81 22 30268 239 79713859
Coronary artery stenosis 94.54 14.81 59 30231 12425 79701673
Arterial disorder 88.63 14.81 32 30258 1958 79712140
Acute coronary syndrome 87.53 14.81 69 30221 21064 79693034
Carotid artery stenosis 86.16 14.81 49 30241 8709 79705389
Arteriosclerosis 78.71 14.81 61 30229 18166 79695932
Splenomegaly 75.87 14.81 63 30227 20691 79693407
Coronary artery disease 75.58 14.81 108 30182 65366 79648732
Peripheral vascular disorder 73.86 14.81 43 30247 7987 79706111
Hypotension 71.74 14.81 39 30251 440278 79273820
Polymerase chain reaction positive 71.27 14.81 18 30272 317 79713781
Condition aggravated 71.19 14.81 52 30238 501072 79213026
Acute kidney injury 69.84 14.81 57 30233 519347 79194751
Myalgia 68.09 14.81 189 30101 185452 79528646
Blood glucose increased 68.09 14.81 141 30149 114834 79599264
Acute lymphocytic leukaemia recurrent 67.83 14.81 34 30256 4690 79709408
Toxicity to various agents 67.71 14.81 38 30252 421502 79292596
Pericardial effusion 61.99 14.81 82 30208 46155 79667943
Cerebral infarction 61.23 14.81 81 30209 45595 79668503
Rheumatoid arthritis 60.46 14.81 5 30285 208465 79505633
Hyperbilirubinaemia 59.28 14.81 59 30231 24459 79689639
Pruritus 59.12 14.81 301 29989 394347 79319751
Amylase increased 58.42 14.81 42 30248 11167 79702931
Concomitant disease aggravated 56.70 14.81 44 30246 13123 79700975
Hyperglycaemia 56.17 14.81 98 30192 70237 79643861
Joint swelling 55.74 14.81 20 30270 288626 79425472
Peripheral artery occlusion 53.95 14.81 24 30266 2533 79711565
Haemoglobin decreased 53.79 14.81 196 30094 221923 79492175
Blast cell crisis 51.95 14.81 12 30278 142 79713956
Pancytopenia 51.42 14.81 159 30131 165586 79548512
Bone marrow failure 51.35 14.81 79 30211 51028 79663070
Gamma-glutamyltransferase increased 50.07 14.81 81 30209 54599 79659499
Concomitant disease progression 49.88 14.81 25 30265 3448 79710650
Arterial stenosis 49.01 14.81 19 30271 1417 79712681
Chronic myeloid leukaemia 48.61 14.81 25 30265 3639 79710459
Drug hypersensitivity 46.46 14.81 28 30262 298888 79415210
Chest pain 46.27 14.81 221 30069 282083 79432015
Abdominal pain upper 44.81 14.81 186 30104 223633 79490465
Confusional state 43.81 14.81 34 30256 317963 79396135
Platelet count increased 43.57 14.81 48 30242 22358 79691740
Cerebrovascular accident 42.74 14.81 143 30147 155149 79558949
Peripheral ischaemia 41.59 14.81 32 30258 9425 79704673
Drug intolerance 41.29 14.81 204 30086 263915 79450183
Acquired gene mutation 40.93 14.81 19 30271 2214 79711884
Overdose 40.57 14.81 10 30280 184196 79529902
Gene mutation 40.54 14.81 20 30270 2666 79711432
Therapeutic response decreased 39.57 14.81 82 30208 66771 79647327
Therapeutic response delayed 38.59 14.81 15 30275 1127 79712971
Arthropathy 38.27 14.81 10 30280 177101 79536997
Arterial occlusive disease 38.04 14.81 29 30261 8427 79705671
Cerebral artery stenosis 36.70 14.81 13 30277 752 79713346
Acne 34.57 14.81 47 30243 27143 79686955
Leukaemia recurrent 34.14 14.81 18 30272 2756 79711342
Haematotoxicity 33.25 14.81 35 30255 15484 79698614
Fall 32.64 14.81 87 30203 487542 79226556
Atrial fibrillation 32.45 14.81 155 30135 197731 79516367
Gangrene 32.32 14.81 27 30263 8937 79705161
Anaemia 32.09 14.81 283 30007 444732 79269366
Leukocytosis 31.42 14.81 58 30232 43397 79670701
Cardiac failure 31.22 14.81 129 30161 154713 79559385
Diabetes mellitus 30.89 14.81 82 30208 78308 79635790
Abdominal pain 30.32 14.81 252 30038 389317 79324781
White blood cell count decreased 29.80 14.81 146 30144 188142 79525956
Angina unstable 29.73 14.81 34 30256 16493 79697605
Drug ineffective 29.46 14.81 266 30024 1080647 78633451
Sinusitis 29.41 14.81 19 30271 195482 79518616
Karyotype analysis abnormal 29.18 14.81 6 30284 39 79714059
Angiopathy 29.05 14.81 23 30267 7059 79707039
Dry skin 28.71 14.81 73 30217 67922 79646176
Cytopenia 28.63 14.81 37 30253 20346 79693752
Infarction 28.16 14.81 19 30271 4563 79709535
Clonal evolution 28.16 14.81 8 30282 224 79713874
Muscle spasms 28.02 14.81 136 30154 174594 79539504
Hypercholesterolaemia 27.97 14.81 39 30251 23056 79691042
Blood lactate dehydrogenase increased 27.97 14.81 52 30238 39118 79674980
Keratosis pilaris 27.36 14.81 6 30284 55 79714043
Thrombocytosis 27.32 14.81 24 30266 8502 79705596
Intentional product use issue 26.95 14.81 12 30278 152100 79561998
Pancreatic toxicity 26.89 14.81 6 30284 60 79714038
Oxygen saturation decreased 26.54 14.81 8 30282 129039 79585059
Pain in extremity 26.35 14.81 232 30058 364306 79349792
Mobility decreased 26.19 14.81 7 30283 122168 79591930
Palpitations 25.92 14.81 106 30184 126504 79587594
Xanthelasma 25.83 14.81 7 30283 164 79713934
Hyponatraemia 25.79 14.81 18 30272 177830 79536268
Labelled drug-food interaction medication error 25.79 14.81 7 30283 165 79713933
Alanine aminotransferase increased 25.68 14.81 126 30164 162444 79551654
Exposure during pregnancy 25.39 14.81 4 30286 101128 79612970
Hepatic function abnormal 25.36 14.81 73 30217 73034 79641064
Hypersensitivity 25.05 14.81 38 30252 262201 79451897
Coronary artery occlusion 25.04 14.81 30 30260 15285 79698813
Musculoskeletal stiffness 25.00 14.81 18 30272 174990 79539108
Glossodynia 23.97 14.81 5 30285 103332 79610766
Arterial thrombosis 23.75 14.81 14 30276 2660 79711438
Central nervous system leukaemia 23.37 14.81 8 30282 418 79713680
Intentional product misuse 23.36 14.81 4 30286 95161 79618937
Transformation to acute myeloid leukaemia 23.12 14.81 10 30280 987 79713111
Blast cell count increased 22.78 14.81 11 30279 1399 79712699
Hepatic infection 22.71 14.81 10 30280 1030 79713068
Product use issue 22.45 14.81 28 30262 209794 79504304
Basophil count increased 22.12 14.81 11 30279 1492 79712606
Chronic myeloid leukaemia (in remission) 21.96 14.81 4 30286 12 79714086
Haemolytic transfusion reaction 21.72 14.81 4 30286 13 79714085
Acoustic neuroma 21.69 14.81 7 30283 304 79713794
Lower respiratory tract infection 21.66 14.81 11 30279 129209 79584889
Oedematous pancreatitis 21.60 14.81 10 30280 1158 79712940
Wheezing 20.99 14.81 9 30281 116655 79597443
Loss of therapeutic response 20.93 14.81 9 30281 875 79713223
Paternal exposure during pregnancy 20.93 14.81 5 30285 69 79714029
Drug interaction 20.88 14.81 84 30206 415099 79298999
Splenitis 20.63 14.81 3 30287 0 79714098
Vascular stenosis 20.62 14.81 8 30282 598 79713500
Skin disorder 20.51 14.81 42 30248 33901 79680197
Asthma 20.49 14.81 13 30277 135082 79579016
Therapy non-responder 20.27 14.81 79 30211 92226 79621872
Blood creatine phosphokinase increased 20.10 14.81 63 30227 66027 79648071
Ischaemic stroke 20.02 14.81 41 30249 33090 79681008
Myeloproliferative neoplasm 19.96 14.81 9 30281 980 79713118
Urinary tract infection 19.87 14.81 47 30243 274465 79439633
Exposure via father 19.80 14.81 5 30285 88 79714010
Cardiovascular disorder 19.72 14.81 29 30261 17996 79696102
Necrosis 19.61 14.81 21 30269 9472 79704626
Dyslipidaemia 19.37 14.81 23 30267 11610 79702488
Liver disorder 19.30 14.81 66 30224 72351 79641747
Suicide attempt 19.26 14.81 4 30286 82928 79631170
Agitation 19.07 14.81 7 30283 99708 79614390
Myopathy toxic 19.06 14.81 9 30281 1089 79713009
Chromosome analysis abnormal 18.90 14.81 6 30284 247 79713851
Chloroma 18.76 14.81 8 30282 762 79713336
Stomatitis 18.58 14.81 17 30273 146740 79567358
Tremor 17.88 14.81 23 30267 170060 79544038
Delirium 17.85 14.81 5 30285 84622 79629476
Hepatotoxicity 17.54 14.81 51 30239 51301 79662797
Pancreatic enzymes increased 17.21 14.81 9 30281 1356 79712742
Metabolic acidosis 17.18 14.81 5 30285 82524 79631574
Suicidal ideation 17.08 14.81 4 30286 76336 79637762
Normal newborn 17.06 14.81 17 30273 7055 79707043
Skin sensitisation 16.80 14.81 8 30282 987 79713111
Discomfort 16.57 14.81 14 30276 125603 79588495
Pyrexia 16.53 14.81 355 29935 678354 79035744
Neoplasm progression 16.39 14.81 50 30240 51632 79662466
Dyslalia 16.23 14.81 8 30282 1064 79713034
Aspartate aminotransferase increased 16.19 14.81 99 30191 138542 79575556
Coronary artery insufficiency 16.19 14.81 5 30285 188 79713910
Vertebral artery stenosis 16.16 14.81 5 30285 189 79713909
Recurrent cancer 16.15 14.81 11 30279 2682 79711416
Therapeutic product effect incomplete 16.11 14.81 18 30272 141627 79572471
Vaginal odour 15.86 14.81 6 30284 419 79713679
Peripheral artery thrombosis 15.79 14.81 12 30278 3471 79710627
Ill-defined disorder 15.67 14.81 3 30287 65872 79648226
Jaundice 15.44 14.81 50 30240 53299 79660799
Supraventricular extrasystoles 15.40 14.81 16 30274 6971 79707127
Cardiac tamponade 14.88 14.81 18 30272 9258 79704840
Coma 14.83 14.81 10 30280 100639 79613459

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
FDA MoA N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000187063 Cytochrome P450 2C8 Inducers
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000191272 UGT1A1 Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic phase chronic myeloid leukemia indication 413847001
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Torsades de pointes contraindication 31722008
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Gastrectomy contraindication 53442002
Diabetes mellitus contraindication 73211009 DOID:9351
Pancreatitis contraindication 75694006 DOID:4989
Hyperglycemia contraindication 80394007 DOID:4195
Hyponatremia contraindication 89627008
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Elevated Serum Lipase contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.89 acidic
pKa2 6.03 Basic
pKa3 3.97 Basic
pKa4 2.2 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 7169791 July 4, 2023 A METHOD FOR THE TREATMENT OF LEUKEMIAS
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 8389537 July 18, 2026 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 8415363 July 18, 2026 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 8415363 July 18, 2026 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 9061029 April 7, 2032 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 9061029 April 7, 2032 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL March 22, 2025 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL March 22, 2025 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL Sept. 22, 2025 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL Sept. 23, 2028 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH ACCELERATED PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) WITH RESISTANCE ORINTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR (TKI) THERAPY
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL March 23, 2029 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.44 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.35 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 8.39 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.60 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.53 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.35 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 6.42 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.38 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.52 CHEMBL
Platelet-derived growth factor receptor beta Kinase Kd 7.80 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 7.77 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 5.26 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.83 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 7 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.33 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.80 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 6.64 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.24 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 4.40 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.06 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.35 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.13 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 6.48 CHEMBL
Insulin receptor Kinase Ki 5.39 PDSP
Mitogen-activated protein kinase 8 Kinase Kd 6.35 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.41 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.35 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.34 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Ki 5.07 PDSP
Angiopoietin-1 receptor Kinase Kd 6 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 7.43 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 7 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5.32 PDSP
Carbonic anhydrase 14 Enzyme Ki 6.65 CHEMBL
Fibroblast growth factor receptor 1 Kinase Ki 5.10 PDSP
Serine/threonine-protein kinase 10 Kinase Kd 5.17 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 7.59 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 7.44 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.72 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 6.48 CHEMBL
Fibroblast growth factor receptor 2 Kinase Ki 5.14 PDSP
Ephrin type-A receptor 6 Kinase Kd 6.19 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.49 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 6.96 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.34 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 7.07 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.89 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.15 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.24 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.96 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 6.14 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.31 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 6.19 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.96 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.44 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.22 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.30 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 6.04 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 6.23 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 6 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.30 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.33 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.77 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 5.06 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Bcr/Abl fusion protein Kinase IC50 9.48 CHEMBL
Ferrochelatase, mitochondrial Enzyme Kd 5.38 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase Kd 5.89 CHEMBL
Integrin-linked protein kinase Kinase Kd 7.70 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.62 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.33 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.10 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.10 CHEMBL
Macrophage colony-stimulating factor 1 receptor Unclassified IC50 6.27 CHEMBL

External reference:

IDSource
4026964 VUID
N0000176124 NUI
D06413 KEGG_DRUG
923288-90-8 SECONDARY_CAS_RN
4026964 VANDF
C1721377 UMLSCUI
CHEBI:52172 CHEBI
NIL PDB_CHEM_ID
CHEMBL255863 ChEMBL_ID
CHEMBL1201740 ChEMBL_ID
DB04868 DRUGBANK_ID
C498826 MESH_SUPPLEMENTAL_RECORD_UI
5697 IUPHAR_LIGAND_ID
8654 INN_ID
F41401512X UNII
644241 PUBCHEM_CID
662281 RXNORM
127956 MMSL
24733 MMSL
d07057 MMSL
012401 NDDF
427941004 SNOMEDCT_US
428468009 SNOMEDCT_US
438943005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0526 CAPSULE 200 mg ORAL NDA 33 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0526 CAPSULE 200 mg ORAL NDA 33 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0592 CAPSULE 150 mg ORAL NDA 33 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0592 CAPSULE 150 mg ORAL NDA 33 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0951 CAPSULE 50 mg ORAL NDA 33 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0951 CAPSULE 50 mg ORAL NDA 33 sections